Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph)
chromosome, which results from a reciprocal translocation between the long arms of the …

Abstract Chronic Myeloid Leukemia is the first malignant disorder with a specific genetic
abnormality in the background. Known as a disease with an inexorable progression to acute …

Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …

Imatinib is considered standard therapy for patients with chronic myelogenous leukemia
(CML), inducing a high rate of hematologic and cytogenetic responses. Despite these …

The introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), has
revolutionized the treatment of chronic myeloid leukemia (CML). By directly targeting the Bcr …

The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …

Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia
chromosome and oncogenic signaling by the resulting Bcr–Abl fusion protein …

Chronic myelogenous leukaemia (CML) is a progressive and often fatal haematopoietic
neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major …

Chronic myeloid leukemia (CML) is a malignant disease that originates in the bone marrow
and is designated by the presence of the Philadelphia (Ph+) chromosome, a translocation …

The deregulated activity of BCR-ABL tyrosine kinase originating from the t (9; 22)
chromosomal translocation has been shown to be necessary and sufficient for the …